{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:10:44Z","timestamp":1792426244505,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010790","name":"Erasmus+","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010790","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease, characterized by multiple strictures and dilatations of the intra- and extrahepatic bile ducts, leading to progressive liver fibrosis, in 10\u201315% cholangiocarcinoma, and ultimately end-stage liver disease. The pathogenesis is poorly understood, but (epi-)genetic factors, mechanisms of innate and adaptive immunity, toxic effects of hydrophobic bile acids, and possibly intestinal dysbiosis appear to be involved. The strong link with inflammatory bowel disease (IBD) is associated with a markedly enhanced risk of colorectal cancer which next to cholangiocarcinoma represents the most serious diagnostic challenge in long-term PSC management. Despite extensive research, no medical treatment has been proven so far to prolong the time to liver transplantation (LTx), which remains the effective treatment in late-stage disease. Recurrence of PSC after LTx is observed in up to 20% of patients. Here, we briefly summarize actual views on PSC pathogenesis and provide an algorithmic approach to diagnostic procedures and recommendations for the management of PSC and its complications. We describe promising treatment options subject to current clinical trials.<\/jats:p>","DOI":"10.1007\/s12072-020-10118-x","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T06:02:44Z","timestamp":1609308164000},"page":"6-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Management of primary sclerosing cholangitis and its complications: an algorithmic approach"],"prefix":"10.1007","volume":"15","author":[{"given":"Michal","family":"Prokopi\u010d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-7799","authenticated-orcid":false,"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"issue":"6","key":"10118_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol 2017;67(6):1298\u20131323. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.022","journal-title":"J Hepatol"},{"issue":"2","key":"10118_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237\u2013267. https:\/\/doi.org\/10.1016\/j.jhep.2009.04.009","journal-title":"J Hepatol"},{"issue":"9","key":"10118_CR3","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/MEG.0b013e3283554bbf","volume":"24","author":"MH Chapman","year":"2012","unstructured":"Chapman MH, Webster GJM, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012;24(9):1051\u20131058. https:\/\/doi.org\/10.1097\/MEG.0b013e3283554bbf","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10118_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01681-z","author":"M Vesterhus","year":"2020","unstructured":"Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020. https:\/\/doi.org\/10.1007\/s00535-020-01681-z (Published online March 28, 2020)","journal-title":"J Gastroenterol."},{"issue":"5","key":"10118_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","volume":"56","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56(5):1181\u20131188. https:\/\/doi.org\/10.1016\/j.jhep.2011.10.025","journal-title":"J Hepatol"},{"issue":"5","key":"10118_CR6","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/hep.24247","volume":"53","author":"NA Molodecky","year":"2011","unstructured":"Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011;53(5):1590\u20131599. https:\/\/doi.org\/10.1002\/hep.24247","journal-title":"Hepatology"},{"issue":"6","key":"10118_CR7","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58(6):2045\u20132055. https:\/\/doi.org\/10.1002\/hep.26565","journal-title":"Hepatology"},{"issue":"12","key":"10118_CR8","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/ibd.22938","volume":"18","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, van Erpecum KJ, van Nieuwkerk KMJ, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012;18(12):2270\u20132276. https:\/\/doi.org\/10.1002\/ibd.22938","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10118_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jhbp.50","volume":"21","author":"A Tanaka","year":"2014","unstructured":"Tanaka A, Tazuma S, Okazaki K, Tsubouchi H, Inui K, Takikawa H. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepato-Biliary-Pancreat Sci 2014;21(1):43\u201350. https:\/\/doi.org\/10.1002\/jhbp.50","journal-title":"J Hepato-Biliary-Pancreat Sci"},{"issue":"5","key":"10118_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrgastro.2016.154","volume":"14","author":"X Jiang","year":"2017","unstructured":"Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol 2017;14(5):279\u2013295. https:\/\/doi.org\/10.1038\/nrgastro.2016.154","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10118_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cgh.2008.03.016","volume":"6","author":"A Bergquist","year":"2008","unstructured":"Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008;6(8):939\u2013943. https:\/\/doi.org\/10.1016\/j.cgh.2008.03.016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10118_CR12","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","volume":"138","author":"TH Karlsen","year":"2010","unstructured":"Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010;138(3):1102\u20131111. https:\/\/doi.org\/10.1053\/j.gastro.2009.11.046","journal-title":"Gastroenterology"},{"issue":"9904","key":"10118_CR13","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","volume":"382","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382(9904):1587\u20131599. https:\/\/doi.org\/10.1016\/S0140-6736(13)60096-3","journal-title":"Lancet"},{"issue":"3","key":"10118_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","volume":"4","author":"N Nakamoto","year":"2019","unstructured":"Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 2019;4(3):492\u2013503. https:\/\/doi.org\/10.1038\/s41564-018-0333-1","journal-title":"Nat Microbiol"},{"issue":"1","key":"10118_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","volume":"69","author":"S Lemoinne","year":"2020","unstructured":"Lemoinne S, Kemgang A, Ben Belkacem K, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 2020;69(1):92\u2013102. https:\/\/doi.org\/10.1136\/gutjnl-2018-317791","journal-title":"Gut"},{"issue":"11","key":"10118_CR16","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1136\/gutjnl-2017-314249","volume":"66","author":"SP O\u2019Hara","year":"2017","unstructured":"O\u2019Hara SP, Karlsen TH, LaRusso NF. Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link? Gut 2017;66(11):1873\u20131877. https:\/\/doi.org\/10.1136\/gutjnl-2017-314249","journal-title":"Gut"},{"issue":"4","key":"10118_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/hep.23810","volume":"52","author":"U Beuers","year":"2010","unstructured":"Beuers U, Hohenester S, de Wenniger LJMB, Kremer AE, Jansen PLM, Elferink RPJO. The biliary HCO3\u2212 umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010;52(4):1489\u20131496. https:\/\/doi.org\/10.1002\/hep.23810","journal-title":"Hepatology"},{"issue":"1","key":"10118_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24691","volume":"55","author":"S Hohenester","year":"2012","unstructured":"Hohenester S, de Wenniger LMB, Paulusma CC, et al. A biliary HCO3\u2212 umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012;55(1):173\u2013183. https:\/\/doi.org\/10.1002\/hep.24691","journal-title":"Hepatology"},{"issue":"4, Part B","key":"10118_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.bbadis.2017.08.021","volume":"1864","author":"K Deutschmann","year":"2018","unstructured":"Deutschmann K, Reich M, Klindt C, et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta BBA Mol Basis Dis 2018;1864(4, Part B):1319\u20131325. https:\/\/doi.org\/10.1016\/j.bbadis.2017.08.021","journal-title":"Biochim Biophys Acta BBA Mol Basis Dis."},{"issue":"10","key":"10118_CR20","doi-asserted-by":"publisher","first-page":"G940","DOI":"10.1152\/ajpgi.00398.2012","volume":"304","author":"JH Zhang","year":"2013","unstructured":"Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013;304(10):G940\u2013G948. https:\/\/doi.org\/10.1152\/ajpgi.00398.2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10118_CR21","doi-asserted-by":"publisher","first-page":"39573","DOI":"10.1038\/srep39573","volume":"6","author":"M Milkiewicz","year":"2016","unstructured":"Milkiewicz M, Klak M, Kempinska-Podhorodecka A, et al. Impaired hepatic adaptation to chronic cholestasis induced by primary sclerosing cholangitis. Sci Rep 2016;6:39573. https:\/\/doi.org\/10.1038\/srep39573","journal-title":"Sci Rep"},{"issue":"12","key":"10118_CR22","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/ecco-jcc\/jjz094","volume":"13","author":"I Guerra","year":"2019","unstructured":"Guerra I, Bujanda L, Castro J, et al. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study. J Crohns Colitis 2019;13(12):1492\u20131500. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz094","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10118_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4291\/wjgp.v9.i1.1","volume":"9","author":"M Ahmed","year":"2018","unstructured":"Ahmed M. Acute cholangitis\u2014an update. World J Gastrointest Pathophysiol 2018;9(1):1\u20137. https:\/\/doi.org\/10.4291\/wjgp.v9.i1.1","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"Suppl 2","key":"10118_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000440829","volume":"33","author":"AE Kremer","year":"2015","unstructured":"Kremer AE, Namer B, Bolier R, Fischer MJ, Oude Elferink RP, Beuers U. Pathogenesis and management of pruritus in PBC and PSC. Dig Dis Basel Switz 2015;33(Suppl 2):164\u2013175. https:\/\/doi.org\/10.1159\/000440829","journal-title":"Dig Dis Basel Switz"},{"issue":"10","key":"10118_CR25","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/00365520410003434","volume":"39","author":"E Bj\u00f6rnsson","year":"2004","unstructured":"Bj\u00f6rnsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2004;39(10):961\u2013968. https:\/\/doi.org\/10.1080\/00365520410003434","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10118_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.gastro.2010.10.014","volume":"140","author":"P Angulo","year":"2011","unstructured":"Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140(1):180\u2013188. https:\/\/doi.org\/10.1053\/j.gastro.2010.10.014","journal-title":"Gastroenterology"},{"issue":"10139","key":"10118_CR27","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet 2018;391(10139):2547\u20132559. https:\/\/doi.org\/10.1016\/S0140-6736(18)30300-3","journal-title":"Lancet"},{"issue":"24","key":"10118_CR28","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3748\/wjg.14.3781","volume":"14","author":"JR Hov","year":"2008","unstructured":"Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008;14(24):3781\u20133791. https:\/\/doi.org\/10.3748\/wjg.14.3781","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10118_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison EM. ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110(5):646\u2013659. https:\/\/doi.org\/10.1038\/ajg.2015.112","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10118_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jhep.2007.11.019","volume":"48","author":"K Said","year":"2008","unstructured":"Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008;48(4):598\u2013605. https:\/\/doi.org\/10.1016\/j.jhep.2007.11.019","journal-title":"J Hepatol"},{"issue":"5","key":"10118_CR31","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.29293","volume":"66","author":"C Schramm","year":"2017","unstructured":"Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J. Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 2017;66(5):1675\u20131688. https:\/\/doi.org\/10.1002\/hep.29293","journal-title":"Hepatology"},{"issue":"6","key":"10118_CR32","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","volume":"66","author":"L Aabakken","year":"2017","unstructured":"Aabakken L, Karlsen TH, Albert J, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol 2017;66(6):1265\u20131281. https:\/\/doi.org\/10.1016\/j.jhep.2017.02.013","journal-title":"J Hepatol"},{"issue":"3","key":"10118_CR33","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/hep.28963","volume":"65","author":"EMG de Vries","year":"2017","unstructured":"de Vries EMG, de Krijger M, F\u00e4rkkil\u00e4 M, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology 2017;65(3):907\u2013919. https:\/\/doi.org\/10.1002\/hep.28963","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10118_CR34","first-page":"43","volume":"13","author":"J Ludwig","year":"1989","unstructured":"Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13(Suppl 1):43\u201349","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10118_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","volume":"60","author":"Y Nakanuma","year":"2010","unstructured":"Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010;60(3):167\u2013174. https:\/\/doi.org\/10.1111\/j.1440-1827.2009.02500.x","journal-title":"Pathol Int"},{"issue":"8","key":"10118_CR36","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weism\u00fcller","year":"2017","unstructured":"Weism\u00fcller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152(8):1975.e8\u20131984.e8. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.038","journal-title":"Gastroenterology"},{"key":"10118_CR37","doi-asserted-by":"publisher","first-page":"109101","DOI":"10.1016\/j.ejrad.2020.109101","volume":"129","author":"KI Ringe","year":"2020","unstructured":"Ringe KI, Bergquist A, Lenzen H, et al. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). Eur J Radiol 2020;129:109101. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109101","journal-title":"Eur J Radiol"},{"issue":"4","key":"10118_CR38","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 2015;63(4):971\u20131004. https:\/\/doi.org\/10.1016\/j.jhep.2015.06.030","journal-title":"J Hepatol"},{"issue":"3","key":"10118_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000431028","volume":"31","author":"LM Hubers","year":"2015","unstructured":"Hubers LM, Beuers U. How to diagnose immunoglobulin G4-associated cholangitis: the jack-of-all-trades in the biliary tract. Visc Med 2015;31(3):185\u2013188. https:\/\/doi.org\/10.1159\/000431028","journal-title":"Visc Med"},{"issue":"4","key":"10118_CR40","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.26999","volume":"60","author":"LJMB de Wenniger","year":"2014","unstructured":"de Wenniger LJMB, Culver EL, Beuers U. Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 2014;60(4):1453\u20131454. https:\/\/doi.org\/10.1002\/hep.26999","journal-title":"Hepatology"},{"issue":"12","key":"10118_CR41","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.cgh.2019.07.011","volume":"17","author":"CL Bowlus","year":"2019","unstructured":"Bowlus CL, Lim JK, Lindor KD. AGA Clinical practice update on surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis: expert review. Clin Gastroenterol Hepatol 2019;17(12):2416\u20132422. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10118_CR42","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1136\/gutjnl-2018-316801","volume":"68","author":"C Rupp","year":"2019","unstructured":"Rupp C, Hippchen T, Bruckner T, et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019;68(12):2170\u20132178. https:\/\/doi.org\/10.1136\/gutjnl-2018-316801","journal-title":"Gut"},{"issue":"3","key":"10118_CR43","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","volume":"155","author":"CY Ponsioen","year":"2018","unstructured":"Ponsioen CY, Arnelo U, Bergquist A, et al. No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis. Gastroenterology 2018;155(3):752.e5\u2013759.e5. https:\/\/doi.org\/10.1053\/j.gastro.2018.05.034","journal-title":"Gastroenterology"},{"issue":"3","key":"10118_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s10620-012-2401-3","volume":"58","author":"PGK Venkatesh","year":"2013","unstructured":"Venkatesh PGK, Navaneethan U, Shen B, McCullough AJ. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 2013;58(3):850\u2013857. https:\/\/doi.org\/10.1007\/s10620-012-2401-3","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10118_CR45","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019;68(8):1356\u20131378. https:\/\/doi.org\/10.1136\/gutjnl-2018-317993","journal-title":"Gut"},{"issue":"2","key":"10118_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/a-1061-7067","volume":"52","author":"AB de Vries","year":"2020","unstructured":"de Vries AB, van der Heide F, Ter Steege RWF, et al. Limited diagnostic accuracy and clinical impact of single-operator peroral cholangioscopy for indeterminate biliary strictures. Endoscopy 2020;52(2):107\u2013114. https:\/\/doi.org\/10.1055\/a-1061-7067","journal-title":"Endoscopy"},{"issue":"11\u201312","key":"10118_CR47","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/apt.13817","volume":"44","author":"B Njei","year":"2016","unstructured":"Njei B, McCarty TR, Varadarajulu S, Navaneethan U. Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 2016;44(11\u201312):1139\u20131151. https:\/\/doi.org\/10.1111\/apt.13817","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10118_CR48","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/hep4.1276","volume":"2","author":"BT Sagvand","year":"2018","unstructured":"Sagvand BT, Edwards K, Shen B. Frequency, risk factors, and outcome of gallbladder polyps in patients with primary sclerosing cholangitis: a case-control study. Hepatol Commun 2018;2(12):1440\u20131445. https:\/\/doi.org\/10.1002\/hep4.1276","journal-title":"Hepatol Commun"},{"issue":"2","key":"10118_CR49","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/liv.14326","volume":"40","author":"LW van Erp","year":"2020","unstructured":"van Erp LW, Cunningham M, Narasimman M, et al. Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. Liver Int Off J Int Assoc Study Liver 2020;40(2):382\u2013392. https:\/\/doi.org\/10.1111\/liv.14326","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"10","key":"10118_CR50","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.cgh.2014.02.008","volume":"12","author":"R Zenouzi","year":"2014","unstructured":"Zenouzi R, Weism\u00fcller TJ, H\u00fcbener P, et al. Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2014;12(10):1733\u20131738. https:\/\/doi.org\/10.1016\/j.cgh.2014.02.008","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"2","key":"10118_CR51","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"P Angeli","year":"2018","unstructured":"Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol"},{"issue":"2","key":"10118_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","volume":"64","author":"EASL Clinical Practice Guidelines","year":"2016","unstructured":"EASL Clinical Practice Guidelines. Liver transplantation. J Hepatol 2016;64(2):433\u2013485. https:\/\/doi.org\/10.1016\/j.jhep.2015.10.006","journal-title":"J Hepatol"},{"issue":"1","key":"10118_CR53","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/lt.24350","volume":"22","author":"T Hildebrand","year":"2016","unstructured":"Hildebrand T, Pannicke N, Dechene A, et al. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis. Liver Transpl 2016;22(1):42\u201352. https:\/\/doi.org\/10.1002\/lt.24350","journal-title":"Liver Transpl"},{"issue":"5","key":"10118_CR54","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jhep.2015.07.005","volume":"63","author":"R Ravikumar","year":"2015","unstructured":"Ravikumar R, Tsochatzis E, Jose S, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 2015;63(5):1139\u20131146. https:\/\/doi.org\/10.1016\/j.jhep.2015.07.005","journal-title":"J Hepatol"},{"issue":"6","key":"10118_CR55","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.transproceed.2013.01.066","volume":"45","author":"MM Wells","year":"2013","unstructured":"Wells MM, Croome KP, Boyce E, Chandok N. Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis. Transplant Proc 2013;45(6):2263\u20132271. https:\/\/doi.org\/10.1016\/j.transproceed.2013.01.066","journal-title":"Transplant Proc"},{"issue":"4","key":"10118_CR56","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/tri.12513","volume":"28","author":"S Pandanaboyana","year":"2015","unstructured":"Pandanaboyana S, Bell R, Bartlett AJ, McCall J, Hidalgo E. Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int 2015;28(4):485\u2013491. https:\/\/doi.org\/10.1111\/tri.12513","journal-title":"Transpl Int"},{"key":"10118_CR57","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.001","author":"E de Vries","year":"2020","unstructured":"de Vries E, Bolier R, Goet J, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial. Gastroenterology 2020. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.001","journal-title":"Gastroenterology"},{"key":"10118_CR58","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.049","author":"PJ Trivedi","year":"2020","unstructured":"Trivedi PJ, Crothers H, Mytton J, et al. Effects of Primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel diseases, based on sex, race, and age. Gastroenterology 2020. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.049 (Published online May 20, 2020)","journal-title":"Gastroenterology"},{"issue":"2","key":"10118_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019;71(2):357\u2013365. https:\/\/doi.org\/10.1016\/j.jhep.2019.04.001","journal-title":"J Hepatol"},{"issue":"1","key":"10118_CR60","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C, et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145\u2013172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"issue":"1 Supplement","key":"10118_CR61","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol 2015;62(1 Supplement):S25\u2013S37. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.023","journal-title":"J Hepatol."},{"issue":"1","key":"10118_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0168-8278(90)90281-u","volume":"11","author":"O Chazouill\u00e8res","year":"1990","unstructured":"Chazouill\u00e8res O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11(1):120\u2013123. https:\/\/doi.org\/10.1016\/0168-8278(90)90281-u","journal-title":"J Hepatol"},{"issue":"3","key":"10118_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hep.1840160315","volume":"16","author":"U Beuers","year":"1992","unstructured":"Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16(3):707\u2013714. https:\/\/doi.org\/10.1002\/hep.1840160315","journal-title":"Hepatology"},{"issue":"10","key":"10118_CR64","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM199703063361003","volume":"336","author":"KD Lindor","year":"1997","unstructured":"Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336(10):691\u2013695. https:\/\/doi.org\/10.1056\/NEJM199703063361003","journal-title":"N Engl J Med."},{"issue":"5","key":"10118_CR65","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell SO, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129(5):1464\u20131472. https:\/\/doi.org\/10.1053\/j.gastro.2005.08.017","journal-title":"Gastroenterology"},{"issue":"3","key":"10118_CR66","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Kowdley KV, Luketic VAC, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatol Baltim Md 2009;50(3):808\u2013814. https:\/\/doi.org\/10.1002\/hep.23082","journal-title":"Hepatol Baltim Md"},{"issue":"3","key":"10118_CR67","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.27074","volume":"60","author":"E Wunsch","year":"2014","unstructured":"Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatol Baltim Md 2014;60(3):931\u2013940. https:\/\/doi.org\/10.1002\/hep.27074","journal-title":"Hepatol Baltim Md"},{"issue":"3","key":"10118_CR68","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","volume":"67","author":"P Fickert","year":"2017","unstructured":"Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017;67(3):549\u2013558. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.009","journal-title":"J Hepatol"},{"key":"10118_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.033","author":"KV Kowdley","year":"2020","unstructured":"Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol 2020. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.033 (Published online March 10, 2020)","journal-title":"J Hepatol."},{"issue":"3","key":"10118_CR70","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 2019;70(3):788\u2013801. https:\/\/doi.org\/10.1002\/hep.30509","journal-title":"Hepatology"},{"issue":"3","key":"10118_CR71","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","volume":"70","author":"GM Hirschfield","year":"2019","unstructured":"Hirschfield GM, Chazouill\u00e8res O, Drenth JP, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 2019;70(3):483\u2013493. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.035","journal-title":"J Hepatol"},{"issue":"10","key":"10118_CR72","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/liv.13402","volume":"37","author":"EMG de Vries","year":"2017","unstructured":"de Vries EMG, F\u00e4rkkil\u00e4 M, Milkiewicz P, et al. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int Off J Int Assoc Study Liver 2017;37(10):1554\u20131561. https:\/\/doi.org\/10.1111\/liv.13402","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"6","key":"10118_CR73","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","volume":"42","author":"S Lemoinne","year":"2018","unstructured":"Lemoinne S, Pares A, Reig A, et al. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Clin Res Hepatol Gastroenterol 2018;42(6):521\u2013528. https:\/\/doi.org\/10.1016\/j.clinre.2018.06.009","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10118_CR74","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study. Aliment Pharmacol Ther 2013;37(6):604\u2013612. https:\/\/doi.org\/10.1111\/apt.12232","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10118_CR75","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","volume":"25","author":"S Rahimpour","year":"2016","unstructured":"Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis JGLD 2016;25(4):457\u2013464. https:\/\/doi.org\/10.15403\/jgld.2014.1121.254.rah","journal-title":"J Gastrointest Liver Dis JGLD"},{"issue":"7","key":"10118_CR76","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol 2019;114(7):1071\u20131079. https:\/\/doi.org\/10.14309\/ajg.0000000000000115","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10118_CR77","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/hep.1840100406","volume":"10","author":"RH Wiesner","year":"1989","unstructured":"Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatol Baltim Md 1989;10(4):430\u2013436. https:\/\/doi.org\/10.1002\/hep.1840100406","journal-title":"Hepatol Baltim Md"},{"issue":"4","key":"10118_CR78","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/gut.38.4.610","volume":"38","author":"U Broom\u00e9","year":"1996","unstructured":"Broom\u00e9 U, Olsson R, L\u00f6\u00f6f L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38(4):610\u2013615","journal-title":"Gut"},{"issue":"5","key":"10118_CR79","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/j.1572-0241.2007.01103.x","volume":"102","author":"G Kaplan","year":"2007","unstructured":"Kaplan G, Laupland K, Butzner D, Urbanski S, Lee S. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007;102(5):1042\u20131049","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10118_CR80","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/00000658-199705000-00004","volume":"225","author":"JA Goss","year":"1997","unstructured":"Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997;225(5):472\u2013483","journal-title":"Ann Surg."},{"issue":"3","key":"10118_CR81","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/lt.21679","volume":"15","author":"E Alabraba","year":"2009","unstructured":"Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009;15(3):330\u2013340. https:\/\/doi.org\/10.1002\/lt.21679.","journal-title":"Liver Transpl"},{"issue":"2","key":"10118_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/lt.21313","volume":"14","author":"J Campsen","year":"2008","unstructured":"Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008;14(2):181\u2013185. https:\/\/doi.org\/10.1002\/lt.21313.","journal-title":"Liver Transpl"},{"issue":"3","key":"10118_CR83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","volume":"53","author":"L Lindstr\u00f6m","year":"2018","unstructured":"Lindstr\u00f6m L, J\u00f8rgensen KK, Boberg KM, et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. Scand J Gastroenterol 2018;53(3):297\u2013304. https:\/\/doi.org\/10.1080\/00365521.2017.1421705","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10118_CR84","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/lt.24496","volume":"22","author":"FD Gordon","year":"2016","unstructured":"Gordon FD, Goldberg DS, Goodrich NP, et al. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: comparison of risk factors between living and deceased donor recipients. Liver Transpl 2016;22(9):1214\u20131222. https:\/\/doi.org\/10.1002\/lt.24496","journal-title":"Liver Transpl"},{"issue":"7","key":"10118_CR85","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4065\/75.7.688","volume":"75","author":"WR Kim","year":"2000","unstructured":"Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75(7):688\u2013694. https:\/\/doi.org\/10.4065\/75.7.688","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10118_CR86","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","volume":"67","author":"EM de Vries","year":"2018","unstructured":"de Vries EM, Wang J, Williamson KD, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut 2018;67(10):1864\u20131869. https:\/\/doi.org\/10.1136\/gutjnl-2016-313681","journal-title":"Gut"},{"issue":"1","key":"10118_CR87","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/hep.30085","volume":"71","author":"JE Eaton","year":"2020","unstructured":"Eaton JE, Vesterhus M, McCauley BM, et al. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning. Hepatology 2020;71(1):214\u2013124. https:\/\/doi.org\/10.1002\/hep.30085","journal-title":"Hepatology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10118-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T01:47:55Z","timestamp":1613699275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10118-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10118"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10118-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"8 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MP received a mobility grant from the Erasmus\u2009+\u2009Programme. UB received grant support via AMC Foundation from a South-African PSC Patient Foundation, grant support via Amsterdam UMC for investigator-initiated studies by Dr. Falk Pharma, Freiburg (Germany), and Intercept, San Diego, CA (USA) and lecture fees from Abbvie, Falk Foundation, Gilead, Intercept.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical requirements"}}]}}